Home›Search›OncoTargets and Therapy

OncoTargets and Therapy

Dove Medical Press Ltd · New Zealand · Est. 1980

ISSN1178-6930eISSN1178-6930

SJR Q2✓ WOS SCIE✓ Scopus / SJR

Removed from DOAJ (2024-09-20). DOAJ's stated reason: Journal not adhering to Best practice. A removal from the Directory of Open Access Journals is a quality/transparency signal — it can mean the journal became inactive or failed DOAJ's re-review criteria. This is not proof of predatory practice, but verify the journal's current status and policies before submitting. Check on DOAJ ↗

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.

📊 Standing in its field

Where this journal ranks among others in the same subject area.

SJR · Scopus

Top 50% in field

Clarivate’s JCR quartile is a separate ranking and may differ

SJR Scorei

0.8

H-Indexi

111

SNIPi

0.667

Total Worksi

6,783

Total Citationsi

154,372

2yr Mean Citednessi

1.65

Open Impact Factor alternative

Retractions

245

Source: Retraction Watch

Aims & Scope

OncoTargets and Therapy is an international, peer-reviewed journal focusing on the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. This journal explores the evidence behind new and existing therapies to aid their informed acceptance by clinicians and treatment adherence by patients.

General Information

Country / RegionNew Zealand

Primary LanguageEnglish

1st Year Published1980

FrequencyAnnual

StatusActive (last: 2026)

Total Publications6,783

Publisher OrgDove Medical Press

OA Since2007

Visit Journal Website

Submission Info

Peer Reviewsingle-anonymous

OA LicenseCC-BY-NC

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✓ Yes

Think.Check.Submit Compliance

thinkchecksubmit.org

8/11 · 73%

✅

Do you know the journal / publisher?

Dove Medical Press Ltd

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

1178-6930 / 1178-6930

✅

Indexed in a trusted database?

WoS, Scopus, PubMed

✅

Peer review process documented?

single-anonymous

❌

Follows ethical publishing standards (COPE)?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

✅

Plagiarism detection in place?

Yes

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

27k

2019

1.2k

27k

2020

532

7.3k

2021

191

1.6k

2022

146

620

2023

142

390

2024

104

278

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

OncologyQ2

Pharmacology (medical)Q2

Subject Classification

Web of Science Categories

Biotechnology & Applied MicrobiologyOncology

Scopus Categories

Pharmacology (medical)Oncology

Research Topics (OpenAlex)

Cancer-related molecular mechanisms researchCircular RNAs in diseasesMicroRNA in disease regulationLung Cancer Treatments and MutationsFerroptosis and cancer prognosisRNA modifications and cancerCancer Immunotherapy and BiomarkersLung Cancer Research StudiesCancer, Hypoxia, and MetabolismCancer Cells and Metastasis

Frequently asked questions about OncoTargets and Therapy

Is OncoTargets and Therapy a predatory journal?

OncoTargets and Therapy was withdrawn from the Directory of Open Access Journals (DOAJ) — DOAJ's stated reason: "Journal not adhering to Best practice" (2024-09-20). Withdrawal is not a predatory verdict, but it is a material editorial signal; it remains indexed in Web of Science, Scopus. Verify the journal's current status on DOAJ and its official site before submitting.

What is the impact factor of OncoTargets and Therapy?

OncoTargets and Therapy is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 1.65.

Is OncoTargets and Therapy indexed in Scopus and Web of Science?

OncoTargets and Therapy is indexed in Web of Science, Scopus.